TrialCell research2023

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.

Yin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.